Release Time：2025-07-16 16:43:01Source：Eyebright
On July 16th, the 19th Beijing Invention and Innovation Competition award ceremony was held in Beijing. This event featured nearly 3,000 innovative achievements from across the country, with Eyebright Medical's Loong Crystal? PR Phakic Intraocular Lens distinguished by winning the gold medal.
This year's competition is co-hosted by the Beijing Invention Association and the Beijing Workers' Technology Association, with support from the Beijing Municipal Science and Technology Commission, the Zhongguancun Management Committee, and the Beijing Federation of Trade Unions.
Eyebright Medical's Loong Crystal? PR Phakic Intraocular Lens is designed for the surgical correction or reduction of myopia in adults. It is also China’s first aspheric phakic intraocular lens and is expected to challenge the long-standing dominance of ICL products in both the Chinese and global markets, thereby accelerating the process of domestic substitution. Following its approval for market launch in January 2025, the Loong Crystal? PR Phakic Intraocular Lens rapidly entered numerous hospitals nationwide, including several ophthalmic groups such as Aier, Puri, Huaxia, Chaoju, and Hevision. Additionally, it was selected as a case study for "New Brands, New Standards, New Achievements" at the 2025 World Health Expo, earning significant recognition from various sectors of society.
Innovation serves as the core driving force behind Eyebright Medical's development. The company actively encourages employees to engage in innovative practices through incentive mechanisms such as the Improvement Innovation Award and the Patent Invention Award. Several products, including the Toric astigmatism correction artificial lens, preloaded artificial lens, orthokeratology lens, and aspheric diffractive multifocal artificial lens, have previously received gold and silver awards at the Beijing Invention and Innovation Competition. Looking ahead, the company will continue to foster an innovative culture, increase R&D investment, and optimize innovation mechanisms to make a substantial contribution to improving the national ophthalmic health level.
